Ionis Pharmaceuticals, Inc. Common Stock
IONS
$58.09
-0.07%
Ionis Pharmaceuticals is a biotechnology company that develops RNA-targeted therapeutics using its proprietary antisense technology platform, focusing on cardiovascular, metabolic, neurological, and rare diseases. As the leading developer of antisense drugs, Ionis has successfully brought multiple products to market through partnerships, including Spinraza with Biogen and Wainua with AstraZeneca, and has recently transitioned to independent commercialization with launches of Tryngolza and Dawnzera. The current investor narrative centers on the company's ability to drive commercial growth from its newly launched products, the recent FDA approval of Zanvastro for a rare brain disorder, and the competitive threats from emerging RNAi therapies, which have contributed to significant stock volatility and a recent sharp sell-off.…
IONS
Ionis Pharmaceuticals, Inc. Common Stock
$58.09
Related headlines
Investment Opinion: Should I buy IONS Today?
Based on the data, I rate IONS as a Hold. The analyst consensus is Buy with an average target of $88.14, implying 51.7% upside, but the stock's recent sell-off and fundamental challenges warrant caution. The thesis is that Ionis's platform and pipeline offer long-term potential, but near-term profitability is elusive and competitive risks are real.
Sign up to view all
IONS 12-Month Price Forecast
The AI assessment is neutral with medium confidence. Ionis's strong revenue growth and pipeline are offset by persistent losses and a high valuation. The stock's recent sell-off has created potential value, but the market is clearly skeptical of near-term prospects. If commercial execution improves and the company shows a path to profitability, the stance could upgrade to bullish. Conversely, any negative clinical or commercial news would reinforce a bearish view. The wide analyst target range (61-115) underscores the uncertainty.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Ionis Pharmaceuticals, Inc. Common Stock's 12-month outlook, with a consensus price target around $88.14 and implied upside of +51.7% versus the current price.
Average Target
$88.14
0 analysts
Implied Upside
+51.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$61 - $115
Analyst target range
The target price range is wide, from a low of $61.00 to a high of $115.00, indicating high uncertainty about the company's future. The low target of $61.00 is only 5% above the current price, suggesting that some analysts see limited upside, possibly due to competitive threats or commercial execution risks. The high target of $115.00 implies a doubling from current levels, reflecting optimism about the potential of the pipeline and new product launches. The wide spread between the low and high targets highlights the high-risk, high-reward nature of the stock, and the recent sell-off after the FDA approval of Zanvastro suggests that the market is focused on the limited commercial potential of ultra-rare disease drugs.
Drowning in data?
Find the real signal!
Bulls vs Bears: IONS Investment Factors
Ionis presents a classic high-risk, high-reward biotech profile. The bull case rests on 87% revenue growth, a robust pipeline, and a strong cash position, while the bear case centers on persistent losses, a rich valuation, and competitive threats from RNAi. Currently, bearish sentiment dominates, as evidenced by the stock's 27% YTD decline and underperformance versus the market. The pivotal tension is whether Ionis can scale commercial revenues from Tryngolza and Dawnzera fast enough to justify its valuation, or whether competition and execution risks will continue to erode investor confidence. Resolution of this commercial execution question will likely determine the stock's trajectory over the next 12 months.
Bullish
- Revenue Surge 87% YoY: Q1 2026 revenue reached $246.1M, up 87% from $131.6M in Q1 2025, driven by commercial product sales and royalties. This demonstrates strong early traction for Tryngolza and Dawnzera, validating the transition to independent commercialization.
- High Gross Margin of 98.8%: Gross margin for Q1 2026 was 98.8%, reflecting the high profitability of antisense therapeutics once commercialized. This provides significant operating leverage potential as revenue scales.
- Strong Balance Sheet with $3.2B Cash: With a current ratio of 3.83 and substantial cash reserves (implied by EV/Sales of 11.15 vs PS of 13.4), Ionis is well-capitalized to fund its pipeline and commercial launches without near-term dilution risk.
- Analyst Consensus Buy with 52% Upside: The average analyst target of $88.14 implies 51.7% upside from the current price of $58.09. With 22 analysts and a mean recommendation of 1.79 (Buy), sell-side sentiment remains constructive despite recent volatility.
Bearish
- Stock Down 27% YTD, Near 52-Week Low: IONS has fallen 27.1% year-to-date and sits just 16% above its 52-week low of $50.01. The stock underperformed the S&P 500 by 40 percentage points YTD, reflecting deep investor pessimism.
- Persistent Losses and Negative Cash Flow: TTM net income is -$925.3M with negative operating cash flow of -$971.3M. The company remains unprofitable, and heavy R&D spending ($210M in Q1 2026) continues to drain cash.
- High Valuation at 13.4x Sales: The trailing PS ratio of 13.4x is expensive for a company with negative earnings. Even the forward PS of ~3.9x assumes aggressive revenue growth to $3.25B, leaving little room for disappointment.
- Competitive Threat from RNAi Therapies: Arrowhead Pharmaceuticals and other RNAi competitors are advancing treatments that could challenge Ionis's antisense platform. The market's fear of technological disruption has contributed to the stock's de-rating.
IONS Technical Analysis
The stock is in a clear downtrend over the past year, with a 1-year price change of -2.1% while the S&P 500 gained 18.65%, resulting in a relative strength of -20.8%. Currently trading at $58.09, the stock is near the lower end of its 52-week range, sitting at approximately 67% of the range between the low of $50.01 and high of $86.74. This positioning near the lows suggests bearish sentiment and potential value, but also reflects the market's concerns about the company's growth prospects.
Beta
0.42
0.42x market volatility
Max Drawdown
-40.1%
Largest decline past year
52-Week Range
$50-$87
Price range past year
Annual Return
-2.1%
Cumulative gain past year
| Period | IONS Return | S&P 500 |
|---|---|---|
| 1m | +7.2% | -0.4% |
| 3m | -22.0% | +4.5% |
| 6m | -21.5% | +13.9% |
| 1y | -2.1% | +19.0% |
| ytd | -27.1% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IONS Fundamental Analysis
Revenue has shown strong growth, with the most recent quarter (Q1 2026) reporting revenue of $246.1 million, an 87% increase year-over-year from $131.6 million in Q1 2025. This growth was driven by commercial product sales, royalties, and collaboration revenue, with commercial revenue of $107.8 million and product sales of $43.0 million in the quarter. However, the revenue trajectory has been uneven, with Q2 2025 benefiting from a one-time milestone of $452.0 million, while other quarters have ranged from $131.6 million to $246.1 million, indicating volatility in partnership-dependent revenue.
Quarterly Revenue
$246091000.0B
2026-03
Revenue YoY Growth
+87.0%
YoY Comparison
Gross Margin
98.8%
Latest Quarter
Free Cash Flow
$-971257000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IONS Overvalued?
Given that Ionis has negative net income (TTM net income of -$925.28 million), the price-to-sales (PS) ratio is the most appropriate valuation metric. The trailing PS ratio stands at 13.4x, while the forward PS ratio is not directly provided but can be estimated using analyst revenue estimates of $3.25 billion, implying a forward PS of approximately 3.9x, suggesting the market expects significant revenue growth. The EV/Sales ratio is 11.15x, which is lower than the PS ratio due to the company's substantial cash and investments, providing a more conservative view of valuation.
PE
-33.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-52.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. Ionis has a TTM net loss of -$925.3M and negative free cash flow of -$971.3M, indicating significant cash burn. The debt-to-equity ratio of 5.35 is high, though much of this is likely convertible debt, and the company's current ratio of 3.83 provides liquidity. Revenue is volatile, swinging from $452M in Q2 2025 to $156.7M in Q3 2025, reflecting dependence on milestone payments. If commercial launches underperform, the company may need to raise capital, potentially diluting shareholders.
FAQ
The key risks are: 1) Financial: Persistent losses and negative cash flow, with TTM net income of -$925M, could lead to dilution if capital is needed. 2) Competitive: RNAi therapies from Arrowhead and others could disrupt Ionis's antisense platform, threatening market share. 3) Commercial execution: The success of Tryngolza and Dawnzera is unproven, and any sales miss could trigger a sell-off. 4) Regulatory: Delays or failures in clinical trials for pipeline drugs could impair growth prospects. The stock's high beta of 0.419 (though low, it is not immune to market swings) and short ratio of 7.02 indicate potential volatility. The most severe risk is a combination of commercial underperformance and competitive pressure, which could drive the stock to its 52-week low of $50.01, a 14% downside from current levels.
The 12-month forecast is uncertain, with three scenarios: Bull case (25% probability) targets $88-$115, driven by strong commercial execution and pipeline progress. Base case (45% probability) targets $70-$88, assuming gradual growth and the stock reaching the analyst average of $88.14. Bear case (30% probability) targets $50-$61, if commercial launches disappoint or competitive threats intensify. The most likely scenario is the base case, with the stock trading around $70-$88. Key assumptions include revenue growth from Tryngolza and Dawnzera and no major clinical setbacks. Investors should monitor quarterly earnings and pipeline updates for signs of which scenario is unfolding.
IONS is trading at a trailing PS of 13.4x, which is high for a company with negative earnings. However, the forward PS of ~3.9x, based on analyst revenue estimates of $3.25B, suggests the market expects substantial growth. Compared to the biotech sector average PS of around 5-7x, IONS appears overvalued on trailing metrics but more reasonably valued on forward metrics. The EV/Sales ratio of 11.15x is lower than the PS ratio due to the company's large cash position, providing a more conservative view. The valuation implies the market expects Ionis to successfully commercialize its pipeline and achieve significant revenue growth. If growth disappoints, the stock could de-rate further.
IONS is a high-risk, high-reward opportunity. The stock trades at $58.09, with an average analyst target of $88.14, implying 51.7% upside. However, the company is unprofitable, with a TTM net loss of -$925M, and faces competitive threats from RNAi therapies. It could be a good buy for investors with a long-term horizon who believe in the commercial potential of Tryngolza and Dawnzera, but it is not suitable for risk-averse investors. The recent FDA approval of Zanvastro adds pipeline value, but the ultra-rare market limits near-term impact. Given the 27% YTD decline, the stock may be undervalued if execution improves, but significant downside risk remains.
IONS is more suitable for long-term investment, given its early-stage commercial products and pipeline. The company is not yet profitable, and earnings visibility is low, making short-term trading risky. The stock's beta of 0.419 suggests lower volatility than the market, but biotech stocks can be unpredictable. With a 1-year price change of -2.1% and significant drawdowns, short-term traders may face challenges. For long-term investors, a minimum holding period of 3-5 years is recommended to allow the pipeline to mature and commercial revenues to scale. The company's strong cash position and multiple potential catalysts (e.g., label expansions, new approvals) support a long-term view. However, investors must be prepared for high volatility and the risk of permanent capital loss if the platform fails to deliver.
